UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

Seminars in oncology, 2015-08, Vol.42 (4), p.539-548

2015

Volltextzugriff (PDF)

The current state of adjuvant therapy of melanoma

The lancet oncology, 2020-11, Vol.21 (11), p.1394-1395

Tarhini, Ahmad A

2020

Volltextzugriff (PDF)

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)

International journal of radiation oncology, biology, physics, 2016-06, Vol.95 (2), p.632-646

2016

Volltextzugriff (PDF)

Adjuvant Therapy of Melanoma

Hematology/oncology clinics of North America, 2021-02, Vol.35 (1), p.73-84

Tarhini, Ahmad A.

2021

Volltextzugriff (PDF)

Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches

The cancer journal (Sudbury, Mass.), 2024-03, Vol.30 (2), p.54-70

2024

Volltextzugriff (PDF)

Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine

Cancer treatment reviews, 2018-12, Vol.71, p.8-18

2018

Volltextzugriff (PDF)

Clinical updates in neoadjuvant immunotherapy for melanoma before surgery

Expert review of clinical immunology, 2024-08, Vol.20 (8), p.927-943

2024

Volltextzugriff (PDF)

Neoadjuvant Therapy in Melanoma: Where Are We Now?

Current oncology reports, 2023-04, Vol.25 (4), p.325-339

2023

Volltextzugriff (PDF)

Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma

Molecular carcinogenesis, 2023-01, Vol.62 (1), p.77-89

2023

Volltextzugriff (PDF)

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Nature reviews. Clinical oncology, 2016-08, Vol.13 (8), p.473-486

2016

Volltextzugriff (PDF)

Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma

Immunotherapy, 2021-08, Vol.13 (12), p.1011-1029

2021

Volltextzugriff (PDF)

Adjuvant Therapy for Melanoma

Current Oncology Reports, 2017-05, Vol.19 (5), p.36, Article 36

2017

Volltextzugriff (PDF)

Tremelimumab: a review of development to date in solid tumors

Immunotherapy, 2013-03, Vol.5 (3), p.215-229

Tarhini, Ahmad A

2013

Volltextzugriff (PDF)

Immune Checkpoint Blockade and Interferon-α in Melanoma

Seminars in oncology, 2015-06, Vol.42 (3), p.436-447

2015

Volltextzugriff (PDF)

Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma

Journal of the American College of Surgeons, 2020-11, Vol.231 (5), p.554-556

2020

Volltextzugriff (PDF)

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

Melanoma research, 2022-02, Vol.32 (1), p.35-44

2022

Volltextzugriff (PDF)

Immunotherapy of Melanoma

Current molecular pharmacology, 2016-08, Vol.9 (3), p.196-207

Tarhini, Ahmad A

2016

Volltextzugriff (PDF)

Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection

Annals of surgical oncology, 2021-11, Vol.28 (12), p.6978-6985

2021

Volltextzugriff (PDF)

One-Anastomosis Gastric Bypass Revision for Gastroesophageal Reflux Disease: Long Versus Short Biliopancreatic Limb Roux-en-Y Gastric Bypass

Obesity surgery, 2022-04, Vol.32 (4), p.970-978

2022

Volltextzugriff (PDF)

Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique

Future oncology (London, England), 2021-06, Vol.17 (17), p.2151-2167

2021

Volltextzugriff (PDF)

Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study

Supportive care in cancer, 2024-06, Vol.32 (6), p.330, Article 330

2024

Volltextzugriff (PDF)

Adjuvant therapy for melanoma

The cancer journal (Sudbury, Mass.), 2012-03, Vol.18 (2), p.192-202

2012

Volltextzugriff (PDF)

ASO Visual Abstract: Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection

Annals of surgical oncology, 2021-12, Vol.28 (Suppl 3), p.678-679

2021

Volltextzugriff (PDF)

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

Quality of life research, 2023-01, Vol.32 (1), p.183-196

2023

Volltextzugriff (PDF)

1 – 25 von 122

Suche als RSS-Feed

Aktive Filter

KollektionElektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(100)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Englisch
(122)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

The current state of adjuvant therapy of melanoma

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)

Adjuvant Therapy of Melanoma

Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches

Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine

Clinical updates in neoadjuvant immunotherapy for melanoma before surgery

Neoadjuvant Therapy in Melanoma: Where Are We Now?

Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma

Adjuvant Therapy for Melanoma

Tremelimumab: a review of development to date in solid tumors

Immune Checkpoint Blockade and Interferon-α in Melanoma

Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

Immunotherapy of Melanoma

Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection

One-Anastomosis Gastric Bypass Revision for Gastroesophageal Reflux Disease: Long Versus Short Biliopancreatic Limb Roux-en-Y Gastric Bypass

Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique

Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study

Adjuvant therapy for melanoma

ASO Visual Abstract: Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

Aktive Filter

Suchergebnisse filtern